Today: 19 April 2026
Unilever share price edges up as tariff jitters drag Europe and dividend date nears
23 February 2026
1 min read

Unilever share price edges up as tariff jitters drag Europe and dividend date nears

London, Feb 23, 2026, 08:39 GMT — Regular session.

  • Unilever (ULVR.L) edged up 0.15% to 5,388 pence during early trading in London
  • European shares dropped, weighed down by renewed jitters over U.S. trade policy.
  • This week, investors are watching Unilever’s Feb. 26 ex-dividend date.

Unilever ticked up in London, adding 0.15% to 5,388 pence in early action. Last closing price: 5,380 pence.

Even a modest uptick drew attention, with sentiment across Europe taking a cautious turn at the open. Unilever often attracts buyers looking for a defensive play when risk appetite fades. Some investors were shifting positions before a dividend cut-off scheduled for later this week.

European shares slipped, weighed down by fresh doubts about U.S. tariffs. The STOXX 600 dropped 0.3% at 0815 GMT, with Germany’s DAX posting the steepest losses. President Donald Trump over the weekend bumped up the global tariff rate to 15%, after initially signaling 10%, according to Reuters.

Unilever’s ordinary shares will trade ex-dividend on Feb. 26, its dividend calendar shows. On Feb. 12, the company announced a quarterly dividend for Q4 2025, payable April 10. Holders as of Feb. 27 will be eligible.

The ex-dividend date marks when new buyers lose eligibility for the next dividend. Typically, the stock price drops by about the dividend’s value as trading opens that day.

Unilever’s renewed dividend focus follows its full-year report earlier this month, where the company projected 2026 underlying sales growth would likely be at the low end of its 4% to 6% multi-year target, pointing to weaker demand in both the U.S. and Europe. Alongside that, a 1.5 billion euro share buyback was unveiled, and management flagged only a “modest” bump in the 2025 operating margin. “It will take time” for these efforts to deliver, RBC Capital Markets analyst James Edwardes Jones remarked. At Quilter Cheviot, consumer staples analyst Chris Beckett described the consumer environment as “okay-ish,” still “far from firing on all cylinders.” Reuters

Unilever’s preferred organic metric is “underlying” sales growth—this figure leaves out currency moves, as well as results from acquisitions and disposals.

Shareholders face the possibility that tariffs could rattle currencies and dent consumer confidence, cutting into volumes at a tough moment for Unilever. The company is already easing up on price hikes to protect its price/mix gains. If developed markets pull back more sharply than forecast, Unilever’s ambition to keep growth on target could face a real challenge.

This week’s risk-off tone has investors on edge, watching to see if the mood sticks. Staples might weather some volatility, though if equity selling gets indiscriminate, they’re not completely sheltered.

Coming soon: Unilever goes ex-dividend on Feb. 26. After that, the Q1 2026 trading statement lands April 30—watch for fresh numbers on sales momentum.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
RELX shares slip at London open as tariff chaos spooks markets; April update looms
Previous Story

RELX shares slip at London open as tariff chaos spooks markets; April update looms

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares
Next Story

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

Go toTop